BHC8:00 AMLe Québec est la première province à inscrire Pr OKEDI MD (suspension injectable à libération prolongée de rispéridone) sur la liste des médicaments remboursés par le régime public pour le traitement de la schizophréniebauschhealth.com
BHC8:00 AMQuébec is the first province to list Pr OKEDI MC (extended-release injectable suspension of risperidone) on the public drug reimbursement formulary for the treatment of schizophreniabauschhealth.com
BHC9:55 AMBausch Health, Canada Inc. et l’Alliance pancanadienne pharmaceutique concluent avec succès leurs négociations, menant à la signature d’une lettre d’intention pour OKEDI MC (suspension injectable à libération prolongée de rispéridone) dans le traitement de la schizophréniebauschhealth.com
BHC9:55 AMBausch Health, Canada Inc. and the pan-Canadian Pharmaceutical Alliance sign letter of intent for public drug plan coverage of Pr OKEDI ® (Risperidone for extended-release injectable suspension) for the treatment of schizophreniabauschhealth.com
BHC5:15 PMBausch Health's Aesthetic Business, Solta Medical, Earns Prestigious Trademark Certification of Thermage® in Chinabauschhealth.com
BHC8:00 AMBausch Health to Participate in RBC Capital Markets 2026 Global Healthcare Conferencebauschhealth.com
BHC5:15 PMBausch Health to Participate in Barclays 30th Annual Leveraged Finance Conferencebauschhealth.com
BHC9:00 AMBausch Health's Dermatology Business, Ortho Dermatologics, Announces the Launch of Biafine®, an Iconic French Skincare Product, Through Convenient Online Orderingbauschhealth.com